BIOCYTOGEN-B Shares Extend Gains with Over 5% Rise Following Strong Preliminary 2025 Results

Stock News02-27

BIOCYTOGEN-B (02315) rose more than 5% again. At the time of writing, the stock was up 5.09% to HK$55.75, with a turnover of HK$6.6351 million.

On February 26, BIOCYTOGEN-B released its preliminary results for the 2025 fiscal year. The group expects revenue of approximately RMB 1.379 billion, representing a year-on-year increase of 40.63%. Net profit attributable to owners of the company is expected to be RMB 173 million, a significant increase of 416.37% compared to the previous year. After adjusting for non-recurring gains and losses, net profit attributable to owners reached RMB 116 million, surging 405.39% year-on-year.

The group's total assets stood at RMB 3.724 billion, an increase of 54.20% from the beginning of the period. Equity attributable to owners of the company was RMB 2.175 billion, a substantial rise of 160.76%.

The growth in operational performance during the reporting period was primarily driven by the continued expansion in overseas markets, coupled with the recovery and rebound of the domestic biopharmaceutical industry, leading to rapid revenue growth for the group.

Furthermore, the group adheres to a strategy of innovation-driven performance growth. By maintaining high-intensity investment in research and development, it has built core technological barriers, ensuring business stability at high gross margin levels. Concurrently, lean management practices have continuously enhanced operational efficiency, contributing to a rapid improvement in the group's profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166481640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 09:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166481640","market":"sh","top_or_hot":-1,"title":"BIOCYTOGEN-B Shares Extend Gains with Over 5% Rise Following Strong Preliminary 2025 Results","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) rose more than 5% again. At the time of writing, the stock was up 5.09% to HK$55.75, with a turnover of HK$6.6351 million.</p>\n<p>On February 26, BIOCYTOGEN-B released its preliminary results for the 2025 fiscal year. The group expects revenue of approximately RMB 1.379 billion, representing a year-on-year increase of 40.63%. Net profit attributable to owners of the company is expected to be RMB 173 million, a significant increase of 416.37% compared to the previous year. After adjusting for non-recurring gains and losses, net profit attributable to owners reached RMB 116 million, surging 405.39% year-on-year.</p>\n<p>The group's total assets stood at RMB 3.724 billion, an increase of 54.20% from the beginning of the period. Equity attributable to owners of the company was RMB 2.175 billion, a substantial rise of 160.76%.</p>\n<p>The growth in operational performance during the reporting period was primarily driven by the continued expansion in overseas markets, coupled with the recovery and rebound of the domestic biopharmaceutical industry, leading to rapid revenue growth for the group.</p>\n<p>Furthermore, the group adheres to a strategy of innovation-driven performance growth. By maintaining high-intensity investment in research and development, it has built core technological barriers, ensuring business stability at high gross margin levels. Concurrently, lean management practices have continuously enhanced operational efficiency, contributing to a rapid improvement in the group's profitability.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B Shares Extend Gains with Over 5% Rise Following Strong Preliminary 2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B Shares Extend Gains with Over 5% Rise Following Strong Preliminary 2025 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-27 09:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) rose more than 5% again. At the time of writing, the stock was up 5.09% to HK$55.75, with a turnover of HK$6.6351 million.</p>\n<p>On February 26, BIOCYTOGEN-B released its preliminary results for the 2025 fiscal year. The group expects revenue of approximately RMB 1.379 billion, representing a year-on-year increase of 40.63%. Net profit attributable to owners of the company is expected to be RMB 173 million, a significant increase of 416.37% compared to the previous year. After adjusting for non-recurring gains and losses, net profit attributable to owners reached RMB 116 million, surging 405.39% year-on-year.</p>\n<p>The group's total assets stood at RMB 3.724 billion, an increase of 54.20% from the beginning of the period. Equity attributable to owners of the company was RMB 2.175 billion, a substantial rise of 160.76%.</p>\n<p>The growth in operational performance during the reporting period was primarily driven by the continued expansion in overseas markets, coupled with the recovery and rebound of the domestic biopharmaceutical industry, leading to rapid revenue growth for the group.</p>\n<p>Furthermore, the group adheres to a strategy of innovation-driven performance growth. By maintaining high-intensity investment in research and development, it has built core technological barriers, ensuring business stability at high gross margin levels. Concurrently, lean management practices have continuously enhanced operational efficiency, contributing to a rapid improvement in the group's profitability.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1166481640","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166481640","pubTimestamp":1772157446,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) rose more than 5% again. At the time of writing, the stock was up 5.09% to HK$55.75, with a turnover of HK$6.6351 million. On February 26, BIOCYTOGEN-B released its preliminary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK4585":"ETF&股票定投概念","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","VT":"世界全股市ETF-Vanguard","BK0216":"研究试验","02315":"百奥赛图-B","BK4588":"碎股"},"translate_title":"继2025年初步业绩强劲后，百奥赛图-B股价延续涨幅，上涨超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"VT":1,"VXUS":1,"02315":1},"content_text":"BIOCYTOGEN-B (02315) rose more than 5% again. At the time of writing, the stock was up 5.09% to HK$55.75, with a turnover of HK$6.6351 million.\nOn February 26, BIOCYTOGEN-B released its preliminary results for the 2025 fiscal year. The group expects revenue of approximately RMB 1.379 billion, representing a year-on-year increase of 40.63%. Net profit attributable to owners of the company is expected to be RMB 173 million, a significant increase of 416.37% compared to the previous year. After adjusting for non-recurring gains and losses, net profit attributable to owners reached RMB 116 million, surging 405.39% year-on-year.\nThe group's total assets stood at RMB 3.724 billion, an increase of 54.20% from the beginning of the period. Equity attributable to owners of the company was RMB 2.175 billion, a substantial rise of 160.76%.\nThe growth in operational performance during the reporting period was primarily driven by the continued expansion in overseas markets, coupled with the recovery and rebound of the domestic biopharmaceutical industry, leading to rapid revenue growth for the group.\nFurthermore, the group adheres to a strategy of innovation-driven performance growth. By maintaining high-intensity investment in research and development, it has built core technological barriers, ensuring business stability at high gross margin levels. Concurrently, lean management practices have continuously enhanced operational efficiency, contributing to a rapid improvement in the group's profitability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166481640","isCrawlerRequest":true}